[
  {
    "ts": null,
    "headline": "Regeneron’s (REGN) Recovery and Dupixent Strength Support BMO’s Outperform Rating",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, BMO Capital analyst Evan Seigerman boosted the firm’s price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $850 from $725 and maintained an Outperform rating on the stock. The analyst noted that the stock has surged […]",
    "url": "https://finnhub.io/api/news?id=b9a736e48bb7355f36c204ec959bbd24b5282f63f28352b0eeb8f93c38a6889b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765213636,
      "headline": "Regeneron’s (REGN) Recovery and Dupixent Strength Support BMO’s Outperform Rating",
      "id": 137738034,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, BMO Capital analyst Evan Seigerman boosted the firm’s price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $850 from $725 and maintained an Outperform rating on the stock. The analyst noted that the stock has surged […]",
      "url": "https://finnhub.io/api/news?id=b9a736e48bb7355f36c204ec959bbd24b5282f63f28352b0eeb8f93c38a6889b"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?",
    "summary": "Regeneron beats earnings, expands partnerships, and gains EU approval for Dupixent.",
    "url": "https://finnhub.io/api/news?id=bc1dea061d8db4e845af0efe1ebf320e8d00b4b0abdcf4f3046341681c9391d7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765205192,
      "headline": "Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?",
      "id": 137734429,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2118024278/image_2118024278.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron beats earnings, expands partnerships, and gains EU approval for Dupixent.",
      "url": "https://finnhub.io/api/news?id=bc1dea061d8db4e845af0efe1ebf320e8d00b4b0abdcf4f3046341681c9391d7"
    }
  },
  {
    "ts": null,
    "headline": "Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?",
    "summary": "Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema.",
    "url": "https://finnhub.io/api/news?id=4024810435f2dd56a947e9d807bd963a4acab3dc9792a6d05bf7ecf7635567dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765204020,
      "headline": "Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?",
      "id": 137732196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema.",
      "url": "https://finnhub.io/api/news?id=4024810435f2dd56a947e9d807bd963a4acab3dc9792a6d05bf7ecf7635567dd"
    }
  }
]